Raynaud Phenomenon

The FDA has granted orphan drug designation to Gesynta Pharma’s GS-248, an oral small molecule, selective membrane-associated prostaglandin E synthase-1 (mPGES-1) inhibitor, for systemic sclerosis, according to a company press release.

Avoiding cold and reducing stress are key to minimizing Raynaud’s phenomenon events, while “good, generic wound care” can be effective in even the most complicated cases, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.

Inability to use one’s fingers and the appearance of new ulcers are among the top five concerns that would prompt treatment escalation in patients with Raynaud’s phenomenon secondary to systemic sclerosis, according to data.

Microvascular complications from the use of calcitonin gene-related peptide antagonists for migraines are uncommon in patients with underlying Raynaud’s syndrome, according to data published in JAMA Network Open.

Fatigue and Raynaud’s syndrome were rated “important” or “very important” as barriers to physical activity in at least 50% of patients with systemic sclerosis, according to survey results published in Arthritis Care & Research.

Infrared thermography is both reliable and reproducible in identifying children with peripheral microvascular disturbances in Raynaud’s phenomenon, according to data published in Pediatric Rheumatology.